본문 바로가기

Pipeline

A vision-driven and value-generating global healthcare group

  • Home
  • R&D
  • Pipeline

Pipeline

이 표는 파이프라인을 나타내는 표로 구분, 프로젝트, 적응중, 비임상시험, 임상시험, 임상1상, 임상2상, 임상3상으로 구성되어 있습니다.
Type Indication MOA Lab code Phase Current Status Partner(s)
Preclinical Phase 1 Phase 2 Phase 3 Approval
In-house Solid Tomor PARP-1 inhibitor IDX1197
P1 ongoing National OncoVenture
In-house Aged related Macular disease Lucentis biobetters IDB0062
Preclinical ongoing
In-house Solid Tumor Avastin biobetters IDB0072
Preclinical ongoing
In-licensed Acute Migraine 5-HT 1F inhibitor Lasmiditan
Pre-registration w/FDA Eli Lilly(US)
In-licensed Chronic lymphocytic leukemia Rituximab biobetters TG-1011
- TGTX(US)
IMD(FDC) Hyperlipidemia Rosuvastatin/Fenofibrate ID-RF
-
Open innovation Parkinson's Disease iCp-Parkin CV-06
Preclinical Cellivery(KOR)
TOP